Efficacy and safety of potassium-competitive acid blockers in eradicating Helicobacter pylori and treating gastro-esophageal reflux disease: A systematic review and meta-analysis.

Key Points

• This review aims to evaluate the efficacy and safety of potassium-competitive acid blockers (PCABs) in treating H. pylori and gastro-esophageal reflux disease (GERD).
• Conducted a systematic review and meta-analysis evaluating PCABs for H. pylori eradication and GERD treatment.
• Used odds ratios (OR) with 95% confidence intervals (95% CI) to measure treatment effects.
• Included comparisons with standard proton pump inhibitors (PPIs) like lansoprazole and rabeprazole.
• Vonoprazan demonstrated significant higher efficacy in eradicating H. pylori compared to lansoprazole (OR 2.84 [1.97-4.11]) and rabeprazole (OR 2.63 [1.05-6.58]).
• For GERD treatment, 8-week and 24-week vonoprazan therapies were similarly effective (OR 2.55 [1.71-3.80] and OR 2.17 [1.00-4.72], respectively).
• Particularly effective for severe reflux esophagitis patients (OR 3.51 [1.65-7.46]).